Compare Viatris Inc (VTRS) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Workday Inc — how do they compare? Viatris Inc trades at $16.25 (market cap $18.69B), while Workday Inc trades at $173.56 (market cap $44.77B). The key difference: Workday Inc is far larger — about 2.4× Viatris Inc's market cap, and Viatris Inc pays a 2.95% dividend while Workday Inc pays none. Which is the better fit depends on your goals.
| VTRS | WDAY | |
|---|---|---|
Market Cap | $18.69B | $44.77B |
Sector | Health | Technology |
52-Week High | $17.86 | $247.69 |
52-Week Low | $9.49 | $112.55 |
Enterprise Value | $30.80B | $44.22B |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Workday (WDAY) trades at $174.5, down 5.26% over 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong revenue growth, reaching $8.45B in 2025, with consistent earnings beats and a high gross margin of 75.77%. Recent news highlights product launches like Workday Adaptive Planning's FedRAMP authorization and an AI-native learning platform, reinforcing its enterprise software leadership.
Outlook remains positive with robust fundamentals and analyst support, though elevated valuation ratios like a P/E of 56.47 pose risks. Key opportunities include AI-driven growth in HR and finance software, while risks involve competitive pressures and market volatility. The consensus price target of $153.33 suggests caution near current levels, but long-term growth prospects are solid.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
